Psoriatic arthritis - etanercept, infliximab and adalimumab: review proposal - June 2013

Review of NICE Technology Appraisal Guidance No. TA199; Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis, and TA220; Golimumab for the treatment of psoriatic arthritis

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance is June 2013.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is no new evidence that would be likely to lead to a change in the recommendations made in the original guidance.  Consequently we propose that both TA199 and TA220 should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

June 2013


This page was last updated: 22 August 2014